Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEN-866 + Vincristine + Temozolomide in AYA Relapsed/Refractory Solid Tumors
NCT04890093Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Miniature drug conjugate
- Countries
- 1
01
Overview
Phase 2, open-label trial of locnartecan in solid tumor, Ewing sarcoma and rhabdomyosarcoma (RMS) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate and Maximum Tolerated Dose / Recommended Phase 2 Dose. Started Oct 2024; status: suspended.
02
Drugs
locnartecan
03
Conditions
solid tumorEwing sarcomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT04890093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890093.